Northern Trust Company of Connecticut’s Nektar Therapeutics NKTR Stock Holding History

Northern Trust Company of Connecticut’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$43K	Hold	253	–	–	﹤0.01%	1951
2013 Q3	$40K	Hold	253	–	–	﹤0.01%	1929
2013 Q2	$44K	Buy	+253	New	+$38.8K	﹤0.01%	1891

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Company of Connecticut's NKTR Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its Nektar Therapeutics (NKTR) position steady in Q4 2013 at 253 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Northern Trust Company of Connecticut first reported a position in NKTR in Q2 2013 and has held it in 3 quarters since. The position peaked at $44K in Q2 2013. 136 funds tracked by Wall St. Rank hold NKTR as of Q4 2013.

Northern Trust Company of Connecticut held 253 shares of Nektar Therapeutics worth $43K as of Q4 2013.
Northern Trust Company of Connecticut left its Nektar Therapeutics share count unchanged in Q4 2013.
Nektar Therapeutics made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1951 holding.
Northern Trust Company of Connecticut first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 3 quarters since.
Northern Trust Company of Connecticut's Nektar Therapeutics position peaked at $44K in Q2 2013.
136 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.